Namuscla 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

namuscla

lupin europe gmbh - mexiletine hydrochloride - myotonic disorders - sydämen hoito - namuscla on tarkoitettu oireenmukaiseen hoitoon myotonia aikuispotilailla, joilla on ei-humuspitoiset myotonic disorders.

Talzenna 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

talzenna

pfizer europe ma eeig - talazoparib - rintojen kasvaimet - antineoplastiset aineet - talzenna on tarkoitettu monoterapiana aikuispotilaille, joilla on ituradan brca1/2-mutaatioita, joilla on her2-negatiivinen paikallisesti edennyt tai metastasoitunut rintasyöpä. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. potilaat, joilla on hormoni-reseptori (hr)-positiivinen rintasyöpä olisi pitänyt käsitellä ennen hormonitoimintaan perustuva hoito, tai katsotaan sopimattomaksi hormonitoimintaan perustuva hoito.

Xospata 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

xospata

astellas pharma europe b.v. - gilteritinib fumarate - leukemia, myeloidi, akuutti - antineoplastiset aineet - xospata on tarkoitettu monoterapiana aikuispotilaille, joilla on uusiutunut tai vaikeahoitoinen akuutti myelooinen leukemia (aml), jossa flt3-mutaatio.

Jyseleca 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

jyseleca

gilead sciences ireland uc, galapagos nv - filgotinib maleate - niveltulehdus, nivelreuma - immunosuppressantit - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Orgovyx 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

orgovyx

accord healthcare s.l.u. - relugolix - prostatiset kasvaimet - endokriinihoito - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

CARVESTAD 6.25 mg tabletti 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

carvestad 6.25 mg tabletti

stada arzneimittel ag - carvedilolum - tabletti - 6.25 mg - karvediloli

CARVESTAD 12.5 mg tabletti 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

carvestad 12.5 mg tabletti

stada arzneimittel ag - carvedilolum - tabletti - 12.5 mg - karvediloli

CARVESTAD 25 mg tabletti 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

carvestad 25 mg tabletti

stada arzneimittel ag - carvedilolum - tabletti - 25 mg - karvediloli

CARVESTAD 3.125 mg tabletti 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

carvestad 3.125 mg tabletti

stada arzneimittel ag - carvedilolum - tabletti - 3.125 mg - karvediloli

CARVEDILOL TAD PHARMA 3.125 mg tabletti 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

carvedilol tad pharma 3.125 mg tabletti

tad pharma gmbh - carvedilolum - tabletti - 3.125 mg - karvediloli